GlassScriptPhysician profile
Syeda Sumera Khan
NPI 1457554529
$4,622.74
in general payments reported to CMS, 2019-2025
30 companies · $846 in 2025
The $846 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $92.33 · 2021: $718 · 2022: $961 · 2023: $616 · 2024: $832 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210 · Education: $83.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.27 |
| Education | $83.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $483.69 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $380.79 | 2019-2025 | Farxiga, Lokelma |
| Baxter Healthcare | $359.80 | 2019-2024 | Renal - Pd, Renal - Amia, Renal - Homechoice Automated Pd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.75 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $301.65 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $274.81 | 2019-2023 | Veltassa |
| Fresenius USA Marketing, INC. | $255.55 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $212.21 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $204.56 | 2021-2024 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $182.73 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $164.59 | 2022 | |
| Glaxosmithkline, LLC. | $150.11 | 2021-2024 | Jesduvroq, Benlysta |
| Akebia Therapeutics INC | $147.29 | 2021-2025 | Vafseo |
| Mallinckrodt Hospital Products INC. | $140.27 | 2021-2025 | Acthar, Terlivaz |
| Vantive US Healthcare LLC | $138.81 | 2025 | Renal - Pd |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $136.67 | 2022 | |
| Mallinckrodt Enterprises LLC | $128.91 | 2019 | |
| Amgen INC. | $127.61 | 2021-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $123.92 | 2022-2024 | |
| Ardelyx, INC. | $72.83 | 2023-2025 | Ibsrela |
| Scpharmaceuticals INC. | $55.77 | 2025 | |
| Daiichi Sankyo INC. | $55.38 | 2022 | |
| Veloxis Pharmaceuticals, INC. | $53.93 | 2019 | |
| Horizon Therapeutics Plc | $44.44 | 2021-2023 | Krystexxa |
| Kyowa Kirin, INC. | $25.66 | 2025 | |
| Abbott Laboratories | $24.87 | 2019 | |
| Apellis Pharmaceuticals, INC. | $21.64 | 2025 | Empaveli |
| Alnylam Pharmaceuticals INC. | $20.67 | 2023 | Givlaari |
| Genzyme Corporation | $16.86 | 2021 | |
| Novo Nordisk INC | $13.97 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syeda Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.